Myeloproliferative Neoplasms (MPN)

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

Original Publication Date
Article Source
External Web Content

Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…

Understanding Clinical Trials

This guide provides information about clinical trials and gives you some things to consider when deciding whether to take part

Financial Resources

A list of organizations & programs that may provide financial resources & other assistance

ASH 2020

Bone Marrow Failure Disease Research Summaries for Patients from the 2020 American Hematology Society Annual Meeting

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.